Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Merck Zocor Discounts Average 37%; Net U.S. Sales Are $885 Mil. In Quarter

  • News

Executive Summary

Merck's average discount for Zocor is 37%, according to figures released in the company's third quarter sales and earnings report on Oct. 18

You may also be interested in...



Medco Will Disclose Drug Cost After Rebates, Discounts Under Settlement

Medco will disclose drug costs after rebates and discounts when the PBM wants to make a therapeutic interchange to a product with a higher AWP

Medco Will Disclose Drug Cost After Rebates, Discounts Under Settlement

Medco will disclose drug costs after rebates and discounts when the PBM wants to make a therapeutic interchange to a product with a higher AWP

Medco IPO Delay: Merck Trades Gross Margin For Cloudy Rebate Calculations

Merck's gross margins would be about five percentage points higher if the company excluded copayments for Medco-managed prescriptions from its revenue line

Table

View full table

Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS040658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By